Exhibitor - Immunomedics - Virtual Exhibit Hall - 2020 Mayo Clinic Oncology Review
COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff as we address the COVID-19 situation. Learn more about COVID-19 online education, resources, and live course cancellations.
Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers. Our proprietary ADC binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. For additional information, please visit our website, Immunomedics.com.